Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Stelara (Ustekinumab) Market Size Forecast: How Large Could The Market Become By 2030?
The stelara (ustekinumab) market has experienced robust expansion over recent years. Projected figures indicate an increase from $11.85 million in 2025 to $12.54 million in 2026, achieving a compound annual growth rate of 5.9%. This historic growth has been driven by factors such as the constraints of traditional immunosuppressants, the growing incidence of autoimmune conditions, compelling evidence of clinical effectiveness, biologic administration within hospital settings, and a strong desire for sustained remission.
Over the coming years, the market for Stelara (ustekinumab) is anticipated to undergo substantial expansion. By 2030, a valuation of $15.57 million is projected, driven by a compound annual growth rate (CAGR) of 5.5%. Several factors are expected to fuel this forecasted growth, including a rise in inflammatory bowel disease cases, widening reimbursement for biologic therapies, a growing patient inclination toward reduced dosing frequency, the impact of biosimilar competition, and advancements in biologic delivery systems. Key trends shaping the forecast period encompass an increasing reliance on targeted biologic treatments, the broadening of autoimmune disease indications, a transition toward long-term maintenance strategies, greater acceptance of subcutaneous biologic formulations, and a rise in at-home administration practices.
Download A Free Sample Report For Comprehensive Market Insights:
Stelara (Ustekinumab) Market Opportunity Drivers: What Is Creating New Revenue Potential?
The growing number of individuals diagnosed with psoriasis is anticipated to drive expansion in the Stelara (ustekinumab) market moving forward. Psoriasis patients are those affected by a chronic autoimmune condition that speeds up skin cell production, leading to red, scaly lesions. This increase in psoriasis cases is linked to various causes, such as enhanced diagnostic methods, environmental factors, hereditary influences, and an older demographic. Stelara (ustekinumab) works by targeting and blocking interleukin-12 and interleukin-23, which assists psoriasis patients by significantly lowering inflammation and plaque buildup, resulting in better skin clearing and sustained symptom control, thereby improving their overall well-being. As an example, in August 2024, a report from the National Psoriasis Foundation (NPF), a U.S.-based nonprofit, indicated that psoriasis affects roughly 3% of American adults aged 20 and older, equating to over 7 million people. Furthermore, it is estimated that about 600,000 adults in the country have psoriasis but have not yet received a diagnosis. Consequently, the rising prevalence of psoriasis patients is projected to boost the Stelara (ustekinumab) market.
Stelara (Ustekinumab) Market Segment Performance And Strategic Opportunities
The stelara (ustekinumab) market covered in this report is segmented –
1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications
2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By End User: Pediatric, Adult, Geriatric
Stelara (Ustekinumab) Market Innovation Trends Driving Future Development
Key players in the stelara (ustekinumab) market are introducing groundbreaking products, specifically biosimilars of this drug, aimed at delivering affordable therapeutic alternatives for individuals suffering from chronic inflammatory disorders. These biosimilars are biologically alike medications engineered to mirror the clinical benefits of Stelara (Ustekinumab) by acting on IL-12 and IL-23 to address autoimmune conditions such as psoriasis and psoriatic arthritis. A notable example occurred in October 2024, when Accord BioPharma Inc., a biopharmaceutical firm headquartered in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for IMULDOSA (ustekinumab-srlf), a biosimilar reference to Johnson & Johnson’s STELARA (ustekinumab). What sets IMULDOSA apart is its extensive list of approved uses, encompassing treatment for adults dealing with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. Additionally, it is uniquely indicated for pediatric patients aged six years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, offering flexibility across different age demographics. Such broad applicability establishes IMULDOSA as a significant therapeutic choice for managing a spectrum of immune-mediated inflammatory conditions.
Stelara (Ustekinumab) Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson
Access The Complete Stelara (Ustekinumab) Market Report:
Stelara (Ustekinumab) Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model